26 April 2012 - Molecular diagnostic company MDxHealth SA (NYSE:MDXH) on Thursday announced with PLUS Diagnostics that they have entered into an agreement to co-promote MDxHealth's ConfirmMDx for Prostate Cancer in the US.

PLUS Diagnostics is a US anatomic pathology company which offers a full range of multi-specialty services, and under the agreement it will build awareness of ConfirmMDx for Prostate Cancer, through its national network of urologists.

ConfirmMDx for Prostate Cancer is a laboratory-developed test (LDT), which was performed at MDxHealth's Irvine, California laboratory, which is intended to assist urologists with identifying men who may safely refrain from unnecessary repeat biopsies.